Case Report: Successful treatment of a novel variant of CARD14-mutated juvenile Pityriasis rubra pilaris with ixekizumab
Pityriasis rubra pilaris is a rare inflammatory papulosquamous skin disease without any approved treatment options. Variants in the CARD14 (caspase recruitment domain family member 14) gene have been identified to play a role in the pathophysiology of atypical juvenile PRP by activating the IL-23/IL...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1637045/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Pityriasis rubra pilaris is a rare inflammatory papulosquamous skin disease without any approved treatment options. Variants in the CARD14 (caspase recruitment domain family member 14) gene have been identified to play a role in the pathophysiology of atypical juvenile PRP by activating the IL-23/IL-17A cytokine axis, highlighting this pathway as a potential target of therapy. Here, we present a case of successful treatment with ixekizumab, a humanized monoclonal anti-IL-17A antibody, in an atypical juvenile PRP (type V) patient with a novel variant of CARD14 mutation. |
|---|---|
| ISSN: | 2296-858X |